ASTRO Annual Meeting

The latest news out of ASTRO Annual Meeting, including researcher interviews and physician perspective.

Meeting News CoveragePerspective

Hemoglobin modifier appears safe, effective for sickle cell disease

December 8, 2015
ORLANDO, Fla. — GBT440, a novel small molecule hemoglobin modifier, reduced hemolysis and improved anemia without causing tissue hypoxia among…
Meeting News CoveragePerspective

Recombinant Factor VIII products increase inhibitor development in severe hemophilia A

December 8, 2015
ORLANDO, Fla. — Recombinant Factor VIII replacement products for severe hemophilia A appeared to increase inhibitor development 1.87-fold…
Meeting News Coverage

Novel treatment provides less toxic approach for pediatric HLH management

December 8, 2015
ORLANDO, Fla. — NI-0501 demonstrated safety and efficacy for the treatment of pediatric patients with hemophagocytic lymphohistiocytosis who…
Meeting News CoveragePerspective

High-dose melphalan plus HSCT extends PFS, OS in newly diagnosed multiple myeloma

December 8, 2015
ORLANDO, Fla. — High-dose melphalan with autologous hematopoietic stem cell transplantation significantly prolonged PFS and OS compared with…
Meeting News CoveragePerspective

Despite advances in triplets, HSCT continues to confer benefit in multiple myeloma

December 7, 2015
ORLANDO, Fla. — Autologous hematopoietic stem cell transplantation should remain a standard of care for younger patients with de novo multiple…
Meeting News Coverage

First-line dasatinib plus pegylated-interferon alpha 2b induces deep molecular responses in CML

December 7, 2015
ORLANDO, Fla. — The first-line combination of dasatinib with pegylated-interferon alpha 2b conferred a high rate of deep molecular response…
Meeting News CoveragePerspective

Hydroxyurea shows promise for stroke prevention in pediatric patients with sickle cell anemia

December 7, 2015
ORLANDO, Fla. — The maximum tolerated dose of hydroxyurea appeared noninferior to chronic transfusions for maintaining transcranial Doppler…
Meeting News CoveragePerspective

Venetoclax produces durable responses in high-risk CLL

December 7, 2015
ORLANDO, Fla. — Venetoclax monotherapy conferred sustained remissions and produced a high overall response rate in patients with relapsed…
Meeting News Coverage

Gene therapy may reduce, eliminate disease symptoms for patients with hemoglobinopathies

December 7, 2015
ORLANDO, Fla. — Gene therapy using autologous hematopoietic stem cells transduced with an experimental lentiviral vector improved the long-term…
Meeting News CoveragePerspective

Luspatercept increases hemoglobin levels, reduces transfusion burden in myelodysplastic syndromes

December 7, 2015
ORLANDO, Fla. — The fusion protein luspatercept led to a sustained increase in hemoglobin levels and reduced the transfusion requirement among…